Suzhou Innovent Biologics has dosed the first patient in a China Phase I clinical trial of its anti-CD47 mAb (IBI188), an inhibitor of the “Don’t Eat Me” pathway. By binding CD47, IBI188 is expected to promote the phagocytosis of tumor cells by macrophages. Innovent plans to conduct several clinical trials to assess the efficacy of IBI188 in multiple tumor types, including non-Hodgkin’s lymphoma and ovarian cancer. Innovent emphasized that IBI188 has a different mechanism that the check point inhibitors PD-1, PD-L1 and CTLA-4.
Source: China Biotoday
